ENTITY
Pharmaron Beijing

Pharmaron Beijing (3759 HK)

186
Analysis
Health Care • China
Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China.
more
bullish•Pharmaron Beijing
•02 Jan 2020 17:52

Pharmaron (åŗ·é¾™åŒ–ęˆ) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade

Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...

Logo
642 Views
Share
bullish•Venus MedTech
•01 Dec 2019 11:18

ECM Weekly (1 Dec 2019) - Venus Medtech, Alphamab, CMC REIT, XD, BAM

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. It has...

Share
bullish•Pharmaron Beijing
•28 Nov 2019 01:41

Pharmaron Beijing: Trading Debut, Valuation Scenario Analysis

Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...

Logo
528 Views
Share
bullish•Pharmaron Beijing
•27 Nov 2019 17:08

Pharmaron (åŗ·é¾™åŒ–ęˆ) A+H: Allocation and Thoughts on Trading

Pharmaron, the second-largest contract research organization (CRO), raised USD 560 m at HKD 39.50/share. In this insight, we will cover the...

Logo
603 Views
Share
bullish•Alibaba
•24 Nov 2019 10:18

ECM Weekly (24 Nov 2019) - Alibaba, OneConnect, Tyro Payments, New Frontier Corp, AlphaMab

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Asia ECM...

Share
x